Compare Kroger Co (KR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Sana Biotechnology Inc — how do they compare? Kroger Co trades at $56.33 (market cap $34.46B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Kroger Co is far larger — about 30.5× Sana Biotechnology Inc's market cap, and Kroger Co pays a 2.56% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KR | SANA | |
|---|---|---|
Market Cap | $34.46B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $5.92 |
52-Week Low | $55.53 | $2.68 |
Enterprise Value | $54.56B | $1.05B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.48, down 0.44% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but maintains a strong cash flow position with $2.08B net cash flow in 2025. Recent corporate actions include dividend payments, and news highlights e-commerce leadership changes and product recalls.
The outlook is balanced; analyst consensus is a Buy with a $68.25 price target, implying 21% upside, supported by stable revenue and margin expansion. Risks include competitive pressures, debt increase, and operational challenges from recent recalls. The stock offers value with a low P/S ratio but faces near-term technical headwinds.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
